MX363609B - Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. - Google Patents

Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.

Info

Publication number
MX363609B
MX363609B MX2015005772A MX2015005772A MX363609B MX 363609 B MX363609 B MX 363609B MX 2015005772 A MX2015005772 A MX 2015005772A MX 2015005772 A MX2015005772 A MX 2015005772A MX 363609 B MX363609 B MX 363609B
Authority
MX
Mexico
Prior art keywords
substituted tricyclic
compounds
kinase inhibitors
tricyclic benzimidazoles
disclosed
Prior art date
Application number
MX2015005772A
Other languages
English (en)
Other versions
MX2015005772A (es
Inventor
Rzymski Tomasz
Zarebski Adrian
Dreas Agnieszka
Osowska Karolina
Kucwaj Katarzyna
Fogt Joanna
Cholody Marek
Czardybon Wojciech
Horvath Raymond
Wiklik Katarzyna
Milik Mariusz
Brzózka Krzysztof
Galezowski Michal
Original Assignee
Selvita Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selvita Sa filed Critical Selvita Sa
Publication of MX2015005772A publication Critical patent/MX2015005772A/es
Publication of MX363609B publication Critical patent/MX363609B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se dan a conocer compuestos bencimidazoles tricíclicos sustituidos, tal como se definen en este documento en la fórmula (I), o sales farmacéuticamente aceptables de los mismos. Los compuestos de la invención inhiben de manera selectiva a CDK8 y, por lo tanto, son útiles para tratar enfermedades relacionadas con esta cinasa, especialmente cáncer colorrectal y melanoma, y otras malignidades sólidas y hematológicas, enfermedades autoinmunes y enfermedades inflamatorias. También se dan a conocer procesos para preparar estos compuestos.
MX2015005772A 2012-11-08 2013-11-07 Bencimidazoles triciclicos sustituidos como inhibidores de cinasas. MX363609B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1220157.0A GB201220157D0 (en) 2012-11-08 2012-11-08 Substitute tricyclic benzimidazoles as kinase inhibitors
PCT/EP2013/073311 WO2014072435A1 (en) 2012-11-08 2013-11-07 Substituted tricyclic benzimidazoles as kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2015005772A MX2015005772A (es) 2015-11-18
MX363609B true MX363609B (es) 2019-03-28

Family

ID=47470315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005772A MX363609B (es) 2012-11-08 2013-11-07 Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.

Country Status (23)

Country Link
US (1) US9745299B2 (es)
EP (1) EP2917217B1 (es)
JP (1) JP6101812B2 (es)
KR (1) KR101812390B1 (es)
CN (1) CN104903321B (es)
AU (1) AU2013343550B2 (es)
BR (1) BR112015010019B1 (es)
CA (1) CA2890643C (es)
CY (1) CY1119084T1 (es)
DK (1) DK2917217T3 (es)
ES (1) ES2628046T3 (es)
GB (1) GB201220157D0 (es)
HR (1) HRP20170802T1 (es)
HU (1) HUE033485T2 (es)
IL (1) IL238693A0 (es)
LT (1) LT2917217T (es)
MX (1) MX363609B (es)
PL (1) PL2917217T3 (es)
PT (1) PT2917217T (es)
RS (1) RS56056B1 (es)
SI (1) SI2917217T1 (es)
SM (1) SMT201700291T1 (es)
WO (1) WO2014072435A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3133075B1 (en) 2014-04-18 2020-12-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US11471446B2 (en) 2015-11-03 2022-10-18 Lu License Ab Compounds for treatment of hypoproliferative disorders
EP3575297B1 (en) 2017-01-30 2024-12-18 Kyoto University Novel compound, and method for producing regulatory t cells
EP3591040A4 (en) * 2017-03-03 2020-11-11 Kyoto University METHOD OF PRODUCTION OF PANCREATIC PROGENITOR CELLS
JP7152784B2 (ja) * 2017-04-03 2022-10-13 京都薬品工業株式会社 新規サイクリン依存性キナーゼ８及び／又は１９阻害剤
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
WO2020038387A1 (zh) * 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
US20220056044A1 (en) * 2018-12-14 2022-02-24 Jiangsu Hengrui Medicine Co., Ltd. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
CN118290350A (zh) * 2019-03-11 2024-07-05 协同医药发展有限公司 治疗铁死亡相关紊乱的杂芳基和双杂环芳基衍生物
US20240360132A9 (en) * 2019-10-03 2024-10-31 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
CN111349094B (zh) * 2020-04-23 2021-02-02 杭州师范大学 一种6H-咪唑[4,5,1-ij]并喹诺酮及其合成方法和应用
TW202204350A (zh) 2020-05-06 2022-02-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
TW202237818A (zh) 2020-11-20 2022-10-01 日商千紙鶴治療公司 成熟化劑
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN116829697A (zh) 2021-02-09 2023-09-29 千纸鹤治疗公司 促熟剂
EP4313050A4 (en) * 2021-03-25 2025-02-12 University of South Carolina CDK8/19 INHIBITORS FOR CYTOKINIC STORM TREATMENT
CA3234008A1 (en) 2021-09-27 2023-03-30 Kyoto University Method for producing t cell
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3239019A1 (en) 2021-11-24 2023-06-01 Regcell Co., Ltd. Human inducibility controllable t-cell and method for preparing same
EP4438048A4 (en) 2021-11-24 2025-10-22 Regcell Co Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED TO T LYMPHOCYTES
WO2023182328A1 (ja) 2022-03-23 2023-09-28 国立大学法人京都大学 制御性ｔ細胞の製造方法
EP4516894A1 (en) 2022-04-25 2025-03-05 Orizuru Therapeutics, Inc. Maturing agent having both of alk5 inhibitory activity and cdk8/19 inhibitory activity
WO2023241627A1 (en) * 2022-06-15 2023-12-21 Insilico Medicine Ip Limited Cdk8/19 dual inhibitors and methods of use thereof
JPWO2024014497A1 (es) 2022-07-14 2024-01-18
WO2024071010A1 (ja) 2022-09-26 2024-04-04 国立大学法人京都大学 Ｔ細胞の製造方法
EP4596684A1 (en) 2022-09-26 2025-08-06 Regcell Co., Ltd. Induced regulatory t cells containing chimeric antigen receptor (car)
JPWO2024166969A1 (es) 2023-02-08 2024-08-15
TW202506995A (zh) 2023-03-29 2025-02-16 日商雷格細胞股份有限公司 人類誘導性調節性ｔ細胞及其製作方法、以及用於治療或預防ｔ細胞相關疾患的醫藥組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2899757B2 (ja) 1989-06-26 1999-06-02 持田製薬株式会社 ジヒドロイミダゾキノリノンオキシムスルホン酸誘導体
US5500423A (en) * 1994-09-09 1996-03-19 Hoechst-Roussel Pharmaceuticals Inc. 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolines
AR030121A1 (es) 2000-08-08 2003-08-13 Sanofi Aventis Derivados de benzimidazol, su preparacion y su aplicacion en terapeutica
AU2002358650A1 (en) 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AU2003240742A1 (en) * 2002-06-07 2003-12-22 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
RU2008101923A (ru) * 2005-08-05 2009-09-10 Астразенека Аб (Se) Трициклические бензимидазолы и их применение в качестве модуляторов метаботропного глутаматного рецептора
BRPI0616722A2 (pt) * 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
JP5766820B2 (ja) * 2011-02-09 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｉ３キナーゼ阻害剤としての複素環化合物

Also Published As

Publication number Publication date
GB201220157D0 (en) 2012-12-26
CN104903321B (zh) 2017-10-24
PT2917217T (pt) 2017-06-07
AU2013343550B2 (en) 2016-09-22
US20150274726A1 (en) 2015-10-01
AU2013343550A1 (en) 2015-05-14
DK2917217T3 (en) 2017-06-19
EP2917217A1 (en) 2015-09-16
HRP20170802T1 (hr) 2017-08-11
PL2917217T3 (pl) 2017-10-31
LT2917217T (lt) 2017-07-25
SI2917217T1 (sl) 2017-08-31
BR112015010019A8 (pt) 2019-09-17
HUE033485T2 (en) 2017-12-28
SMT201700291T1 (it) 2017-07-18
IL238693A0 (en) 2015-06-30
CY1119084T1 (el) 2018-01-10
KR20150091074A (ko) 2015-08-07
CA2890643C (en) 2018-05-22
MX2015005772A (es) 2015-11-18
US9745299B2 (en) 2017-08-29
CN104903321A (zh) 2015-09-09
RS56056B1 (sr) 2017-09-29
WO2014072435A1 (en) 2014-05-15
EP2917217B1 (en) 2017-03-08
KR101812390B1 (ko) 2017-12-26
JP6101812B2 (ja) 2017-03-22
CA2890643A1 (en) 2014-05-15
BR112015010019A2 (pt) 2017-07-11
BR112015010019B1 (pt) 2022-08-09
JP2016503408A (ja) 2016-02-04
ES2628046T3 (es) 2017-08-01

Similar Documents

Publication Publication Date Title
MX2015005772A (es) Bencimidazoles triciclicos sustituidos como inhibidores de cinasas.
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12017502141A1 (en) Compounds and their methods of use
NZ630925A (en) Pyrazolopyrimidine compounds as kinase inhibitors
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
MX2015007057A (es) Derivados novedosos de bencimidazol como inhibidores de cinasas.
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX2012013197A (es) Inhibidores de indazol de cinasa.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX2014013090A (es) Derivados de pirrolotriazinona.
MX336022B (es) Activadores de pkm2 bicíclicos.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2016008042A (es) Derivados de imidazopirazinona.
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
MX2016000487A (es) Piridina-2-carboxamidas como nematicidas.
NZ712369A (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
PH12013502079A1 (en) New indolinone protein kinase inhibitors
GB201212586D0 (en) Cancer treatment
GB201016442D0 (en) Novel acridine derivatives
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази